What does this research mean for the field?

The optimized inactive-state Cbl-b inhibitor compound 16 achieves sufficient oral exposure to significantly inhibit tumor growth in a murine colon-cancer model. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

The aim is to optimize Cbl-b inhibitors to enhance their effectiveness in cancer immunotherapy.

May 17, 2026

Optimization and In Vivo Characterization of a Series of Cbl-b Inactive-State Inhibitors

Key Points

The aim is to optimize Cbl-b inhibitors to enhance their effectiveness in cancer immunotherapy.
Optimized a series of inactive-state Cbl-b inhibitors through modification of chemical structures.
Identified compound 16, focusing on its biochemical potency and cellular activity.
Evaluated pharmacokinetic properties and in vivo effects on tumor growth.
Compound 16 demonstrated significant tumor growth inhibition in a murine CT26 colon-cancer model (p<0.01).
Despite high IV clearance, compound 16 showed sufficient oral exposure to be effective.
Achieved a favorable balance of potency and pharmacokinetic properties in vitro.

Abstract

Casitas B-lineage lymphoma-b (Cbl-b), an E3 ubiquitin ligase, is a key negative regulator of immune function, and its inhibition is a promising strategy for cancer immunotherapy. Here, we show the optimization of a series of inactive-state Cbl-b inhibitors to improve their potency and pharmacokinetic properties. Through systematic modification of a benzylic amine and a linker region, compound 16 was identified, which demonstrates a favorable balance of biochemical potency, cellular activity, and in vitro ADME properties. Despite exhibiting high IV clearance in vivo, compound 16 achieved oral exposures sufficient to demonstrate significant tumor growth inhibition in a murine CT26 colon-cancer model.

Perguntar à IA

Bookmark